Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)
81.60
-1.40 (-1.69%)
Sep 8, 2026, 12:01 PM CST
Foresee Pharmaceuticals Revenue
Foresee Pharmaceuticals had revenue of 181.65M TWD in the quarter ending June 30, 2026, with 62.70% growth. This brings the company's revenue in the last twelve months to 471.13M, up 6.41% year-over-year. In the year 2025, Foresee Pharmaceuticals had annual revenue of 431.27M with 3.01% growth.
Revenue (ttm)
471.13M
Revenue Growth
+6.41%
P/S Ratio
27.75
Revenue / Employee
n/a
Employees
n/a
Market Cap
13.08B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 431.27M | 12.59M | 3.01% |
| Dec 31, 2024 | 418.69M | 223.65M | 114.67% |
| Dec 31, 2023 | 195.04M | -106.47M | -35.31% |
| Dec 31, 2022 | 301.51M | 75.48M | 33.39% |
| Dec 31, 2021 | 226.03M | -4.41M | -1.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Grape King Bio | 10.12B |
| YungShin Global Holding | 7.84B |
| Standard Chemical & Pharmaceutical | 7.08B |
| Synmosa Biopharma | 6.68B |
| TTY Biopharm Company | 6.65B |
| ScinoPharm Taiwan | 3.07B |
| Center Laboratories | 1.66B |
| Orient Pharma | 1.52B |